General

Showing 1921–1936 of 2282 results

Article: PP4.4 A retrospective study of 109 patients with essential thrombocythemia with a focus on the delay in the diagnosis
€3.03 Add to cart
Article: PP4.5 Functional in vitro evaluation of T cells generated from minor H antigen-TCR transduced human hematopoietic stem cells using the OP9-DL1 coculture system
€3.03 Add to cart
Article: PP40 Anti-Pd1 inhibitor follow by Allo Stem cell transplantation in 3 heavily pretreated lymphoma’s patients: Experience from Institut Jules Bordet
€3.03 Add to cart
Article: PP41 The role of myeloid-derived suppressor cells in autologous hematopoietic stem cell transplantation
€3.03 Add to cart
Article: PP42 Th17 impact on xenogeneic graft-versus-host disease
€3.03 Add to cart
Article: PP43 Graft-versus-host disease (GVHD) of the central nervous system (CNS) after allogeneic hematopoietic cell transplantation (alloHCT): case report
€3.03 Add to cart
Article: PP44 CORD BLOOD CELLS: a rapid alternative method for antibody screening in patients under therapeutic CD38-targeting antibody
€3.03 Add to cart
Article: PP45 Blood transfusion in Sickle Cell Disease. Retrospective study in ZNA Hospitals (Antwerp)
€3.03 Add to cart
Article: PP46 Blood transfusion management in the new era of immune therapy: experience from Dienst voor het Bloed, Rode Kruis-Vlaanderen
€3.03 Add to cart
Article: PP47 mBetrixaban: Impact on routine and specific coagulation assays – A practical laboratory guide
€3.03 Add to cart
Article: PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis
€3.03 Add to cart
Article: PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH
€3.03 Add to cart
Article: PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice
€3.03 Add to cart
Article: PP50 Non-invasive fetal genotyping of RHCE C/c and E alleles in allo-immunized pregnant women: evaluation of a 7-year experience
€3.03 Add to cart
Article: PP51 Impact of Th17 cell population on xenogeneic graft-versus-host disease
€3.03 Add to cart
Article: PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab
€3.03 Add to cart

Article: PP4.4 A retrospective study of 109 patients with essential thrombocythemia with a focus on the delay in the diagnosis

Article: PP4.5 Functional in vitro evaluation of T cells generated from minor H antigen-TCR transduced human hematopoietic stem cells using the OP9-DL1 coculture system

Article: PP40 Anti-Pd1 inhibitor follow by Allo Stem cell transplantation in 3 heavily pretreated lymphoma’s patients: Experience from Institut Jules Bordet

Article: PP41 The role of myeloid-derived suppressor cells in autologous hematopoietic stem cell transplantation

Article: PP42 Th17 impact on xenogeneic graft-versus-host disease

Article: PP43 Graft-versus-host disease (GVHD) of the central nervous system (CNS) after allogeneic hematopoietic cell transplantation (alloHCT): case report

Article: PP44 CORD BLOOD CELLS: a rapid alternative method for antibody screening in patients under therapeutic CD38-targeting antibody

Article: PP45 Blood transfusion in Sickle Cell Disease. Retrospective study in ZNA Hospitals (Antwerp)

Article: PP46 Blood transfusion management in the new era of immune therapy: experience from Dienst voor het Bloed, Rode Kruis-Vlaanderen

Article: PP47 mBetrixaban: Impact on routine and specific coagulation assays – A practical laboratory guide

Article: PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis

Article: PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH

Article: PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice

Article: PP50 Non-invasive fetal genotyping of RHCE C/c and E alleles in allo-immunized pregnant women: evaluation of a 7-year experience

Article: PP51 Impact of Th17 cell population on xenogeneic graft-versus-host disease

Article: PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab